Dilon Technologies Announces the Beginning of Enrollment in its Pivotal Trial of the Next Generation MarginProbe™ 2 Used in Real-Time Margin Assessment

First Patient Enrollment

Dilon Technologies Inc. announced today the enrollment of its first patient in the Prospective, Single-Arm, Multi-Center Pivotal Trial for its next generation MarginProbe 2 product used in real-time margin assessment.

Dr. Mehran Habibi, MD

“It is thrilling to witness the development and launch of the MarginProbe 2 study. Being actively involved in advancing real-time margin assessment technology remains a significant and ongoing commitment for me,” stated Dr. Mehran Habibi, MD, who is the Chief of Breast Surgery of the Western Region of Northwell Health in NY and Director of the Breast Program at Staten Island University Hospital. Dilon Technologies has 5 (five) US hospital sites approved and ready to begin enrolling patients. “I have already experienced great results with the current MarginProbe technology. Being a part of the trial for a next generation MarginProbe 2 that may yield a higher sensitivity may reduce the number of false negatives and help us do even better for our patients,” stated Dr. Lori Alfonse, DO, Deputy Physician-in-Chief at the Lehigh Valley Health Network Cancer Institute based in Allentown, PA.

Learning Group Data

In the learning group, sensitivity in the MarginProbe 2 ranged between 75% – >90% sensitivity. Dilon has not seen other technology showing publicly available data with comparable sensitivity rates. “I’ve already been able to bring re-excision rates down to 4.5% using the current MarginProbe in my practice. Participating in a trial for the next generation device is extremely exciting to hopefully improve upon that,” said Dr. Vincent Reid, MD, breast surgeon from Mercy Medical Center in Iowa.

Moving Forward

Dilon Technologies looks to continue building evidence around its MarginProbe platform that already has over 12 peer-reviewed publications demonstrating reduction in re-excision rates. “We remain committed to being a leader in women’s healthcare by providing technology for patients that will improve their outcomes. MarginProbe is beginning to become an integral component of breast surgery for more surgeons across the United States each month,” stated George Makhoul, CEO of Dilon Technologies.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.